| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | 0.1 | 0.2 |
| mRNA | R428 | CTRPv2 | pan-cancer | AAC | -0.058 | 0.2 |
| mRNA | alvocidib | CTRPv2 | pan-cancer | AAC | -0.067 | 0.2 |
| mRNA | BRD-K75293299 | CTRPv2 | pan-cancer | AAC | 0.094 | 0.2 |
| mRNA | MLN2238 | CTRPv2 | pan-cancer | AAC | 0.045 | 0.2 |
| mRNA | BRD-K16130065 | CTRPv2 | pan-cancer | AAC | 0.093 | 0.2 |
| mRNA | bafilomycin A1 | CTRPv2 | pan-cancer | AAC | 0.19 | 0.2 |
| mRNA | pifithrin-mu | CTRPv2 | pan-cancer | AAC | 0.045 | 0.2 |
| mRNA | TPCA-1 | CTRPv2 | pan-cancer | AAC | -0.042 | 0.2 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.043 | 0.2 |